Table 1 Reported Lab Values for Available ADT Options

From: Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Generation

Drug (Reference)

Proportion of patients

T ≤ 50 ng/dL

T ≤ 20 ng/dL

Nadir T ≤ 10 ng/dL

No T Escape > 50 ng/dL

PSA decline >90% or to <4 ng/mL

1

Bicalutamide [121]

    

39

Flutamide [122, 123]

    

13−40

Nilutamide [124]

    

n/d

Cyproterone acetate [125, 126]

    

4−70

2

SC-leuprolide acetate [26, 32, 38]

94−99

90−96

97

98−100

91−95

IM-leuprolide acetate [25, 33, 127]

93−95

66−79

n/d

91−98

51−87

Triptorelin [27, 31, 35, 128, 129]

93−98

25−79

n/d

93−99

81

Goserelin [28, 36, 130]

65−91

55

n/d

91

n/d

Degarelix [43, 45, 46, 89]

99−100

63

n/d

97−98

69−95

Relugolix [64]

n/d

n/d

n/d

n/d

n/d

3

Abiraterone [131, 132]

n/d

n/d

n/d

n/d

19

Enzalutamide [59, 60]

    

25−47

Apalutamide [133]

    

42−43

Darolutamide [134]

    

30

  1. Gray cells: Not relevant as mechanism does not affect serum testosterone
  2. Data should not be directly compared, as numerous sources, different doses, and time points are used
  3. n/d no data
Back to article page